Transarterial chemoembolization with bleomycin and lipiodol: a novel treatment for giant hepatic haemangiomas
Polish Journal of Radiology · 19.09.2025 · 90 · 465-470
DOI: 10.5114/pjr/210131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Polish Journal of Radiology, online erschienen am 19.09.2025. Verfasst von Krzysztof Pyra und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology and Neuroradiology, Medical University of Lublin, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
Giant hepatic haemangiomas are among the most common benign liver tumours, with an incidence ranging from 4.0% to 20.0%. Large hepatic haemangiomas can cause symptoms such as pain and bleeding. There is currently no gold standard in their treatment. One of the methods is transarterial bleomycin-lipiodol embolisation (B/LE). The aim of this study is to evaluate the efficacy of treating hepatic haemangiomas with B/LE. Material and methods We retrospectively reviewed 44 patients treated with B/LE between February 2021 and June 2022 in the Department of Interventional Radiology and Neuroradiology, Medical University of Lublin. Before the procedure, all patients were examined by magnetic resonance imaging (MRI) or computed tomography. Vascularised lesions were embolised by intraarterial administration of a mixture of bleomycin and lipiodol, closing the vascularisation of the lesion, which was confirmed by control angiography. All patients were followed up clinically and by MRI for an average of 6 months.
Results
The size of the examined haemangiomas before the procedure ranged from 5 to 16 cm. After the first procedure, 28 out of 44 patients had an essential reduction in the size of the haemangioma, while 16 patients had the procedure repeated. Eventually, the size of the haemangiomas decreased significantly (p ≤ 0.05). The average reduction in volume was 67.22%. Technical success, described as the reduction of blood supply to the haemangioma, was achieved in all the cases.
Conclusions
Transarterial B/LE is an effective procedure resulting in reduced size of haemangiomas and alleviation of symptoms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Radiology and Neuroradiology, Medical University of Lublin, Poland.
- Department of Interventional Radiology, Oncointerventional Unit, Semmelweis University, Budapest.
- Department of Interventional Radiology, Cardarelli Hospital, Naples, Italy.
- Department of Medical Imaging, Holycross Cancer Cross, Kielce.
- Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Poland.
- Department of Cardiovascular Surgery, John Paul's Western Hospital in Grodzisk Mazowiecki, Grodzisk Mazowiecki, Poland.
Zitieren
APA
Pyra, K., Mikos, E., Szmygin, M., Światłowski, Ł., Bibok, A., Giurazza, F., Sojka, M., Kuczyńska, M., Kopycki, D., Kidziński, R., Lesiuk, P., Cichoż-Lach, H., & Drelich-Zbroja, A. (2025). Transarterial chemoembolization with bleomycin and lipiodol: a novel treatment for giant hepatic haemangiomas. Polish Journal of Radiology, 90, 465-470. https://doi.org/10.5114/pjr/210131
Vancouver
Pyra K, Mikos E, Szmygin M, Światłowski Ł, Bibok A, Giurazza F, et al. Transarterial chemoembolization with bleomycin and lipiodol: a novel treatment for giant hepatic haemangiomas. Polish Journal of Radiology. 2025;90:465-470. doi:10.5114/pjr/210131
BibTeX
@article{Pyra2025,
author = {Pyra, Krzysztof and Mikos, Eryk and Szmygin, Maciej and Światłowski, Łukasz and Bibok, Andreas and Giurazza, Francesco and Sojka, Michał and Kuczyńska, Maryla and Kopycki, Damian and Kidziński, Rafał and Lesiuk, Piotr and Cichoż-Lach, Halina and Drelich-Zbroja, Anna},
title = {Transarterial chemoembolization with bleomycin and lipiodol: a novel treatment for giant hepatic haemangiomas},
journal = {Polish Journal of Radiology},
year = {2025},
volume = {90},
pages = {465--470},
doi = {10.5114/pjr/210131}
}
EUVIMED